| Second anti-TNF (n=3237) | RTX (n=1018) | |
|---|---|---|
| Age (years), mean (SD) | 55.9 (12.3) | 57.8 (12.3) |
| Gender: n (%) female | 2573 (79.5) | 791 (77.7) |
| RA duration (years), Median (IQR) | 12 (6, 19) | 10 (5, 18) |
| DAS28 score at switch, mean (SD) | 5.6 (1.5) | 6.0 (1.3) |
| HAQ at switch, mean (SD) | 1.9 (0.6) | 2.0 (0.6) |
| Steroid use (%) | 57 | 68 |
| Stopped 1st anti-TNF for adverse event: n (%) | 1009 (31.2) | 269 (26.4) |
| Follow-up (pyrs) | 2688 | 866 |
| Median follow-up (pyrs; IQR) | 1.0 (0.7, 1.0) | 1.0 (0.7, 1.0) |
| 1st serious infections, n | 158 | 47 |
| Median time to infection (years; IQR) | 0.3 (0.2, 0.5) | 0.3 (0.2, 0.5) |
| Crude incidence rate 1st SI/1000 pyrs (95% CI) | 60 (51, 70) | 56 (42, 74) |
| Unadjusted HR (95% CI) | Referent | 0.90 (0.65, 1.25) |
| Age & gender adjusted HR (95% CI) | Referent | 0.85 (0.61, 1.17) |
| Fully adjusted by IPTW HR (95% CI)* | Referent | 0.74 (0.37, 1.50) |
↵* IPTW HR adjusted by age, disease duration, DAS28 and HAQ at switch, sex, smoking, use of steroids before switch, reason stop 1st anti-TNF, number prior DMARDs, diabetes, lung involvement, heart disease, liver disease, renal disease, previous cancer, tuberculosis and year of starting a biologic.